Floatz logo

(Z)-Endoxifen

Breast Carcinoma

National Cancer Institute (NCI)UNKNOWNPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

208 Active assets in the Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab
SWOG Cancer Research Network
Phase 4BBB
Tamoxifen
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB
Pertuzumab
SWOG Cancer Research Network
Phase 3BBB

View all 50 →

Same molecule, other indications

(Z)-Endoxifen is also rated in:

ductal breast carcinoma in situActive
BB
Indicative · Phase 2
64 / 100
View asset →
breast cancerActive
CCC
Indicative · Phase 2
53 / 100
View asset →
lobular breast carcinoma in situActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →